Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorecivivint in moderate to severe knee osteoarthritis
NCT04385303Phase 3Completed
- Sponsor
- Biosplice Therapeutics
- Start
- May 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lorecivivint in knee osteoarthritis (OA), sponsored by Biosplice Therapeutics. Started May 2020; status: completed.
02
Drugs
lorecivivint
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04385303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385303.